16.07.2017 • NewsElaine BurridgeTiO2Engineering

Argex Raises Funds for TiO2 Project

(c) David Burton/FuseGetty
(c) David Burton/FuseGetty

Canada’s Argex Titanium has been given conditional approval by the Toronto Stock Exchange for a private placement aimed at raising gross proceeds of Can$3.5 million to fund the completion of engineering on a proposed titanium dioxide (TiO2) plant in Valleyfield, Quebec.

The Montreal-headquartered company said its newly developed production process is set to disrupt the $16 billion global TiO2 industry, claiming it provides significant cost and environmental advantages over current technologies.

At last month’s Annual General Meeting, Argex revealed its latest plans for the project, which has been in preparation since the positive results of a feasibility study in 2013. The company said that it had hired a few additional engineers and contracted with Canadian firms WSP and SNC Lavalin in March to begin basic engineering. In addition, different ore feedstocks have been tested and are yielding consistent product, which Argex said meets or exceeds industry specifications.

The project is now in the advanced planning stages for construction of a 90,000 t/y plant to be commissioned by the end of 2019. A technology center, which will be a smaller scale replica of the commercial plant, will also be built in 2018. A site for the center, which will produce 12 t/y of the pigment, will be announced in the second half of 2017.

Argex is currently in discussions to license the technology and the company’s management is negotiating purchase agreements with large industry players for offtake from the first train’s production of 30,000 t/y.

Annual global consumption of TiO2 is 6 million t, according to Argex, which said it will initially produce less than 2% of demand worldwide.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.